EyePoint EYPT is a clinical-stage biotechnology company focused on developing treatments for serious retinal diseases that can lead to vision loss.
The company’s growth story largely depends on the success of its lead drug candidate, Duravyu (vorolanib intravitreal insert), which is being developed to treat wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The candidate uses the company’s Durasert E technology to deliver vorolanib, a drug designed to block signals involved in abnormal blood vessel growth and leakage in the retina. The insert is being developed to release the medicine over an extended period, allowing patients to receive treatment less frequently than with conventional eye injections such as Regeneron’s REGN Eylea (aflibercept), a widely used standard-of-care anti-VEGF treatment.
EyePoint is evaluating Duravyu in two pivotal phase III studies, LUGANO and LUCIA, in wet AMD. The results from the LUGANO study, announced in August 2026, were mixed, as the study failed to meet its primary endpoint in the overall patient population. Despite missing the primary endpoint, Duravyu showed encouraging results on key secondary endpoints. The drug demonstrated the potential to reduce treatment burden, lower the need for additional treatments and maintain favorable safety and disease control.
The company expects to report top-line data from the LUCIA study in the fourth quarter of 2026. Positive data could strengthen the drug’s potential and support EyePoint’s plan to file a new drug application (NDA) in the first half of 2027.
Year to date, shares of EyePoint have plunged 83.5% against the industry’s 0.7% growth.
Image Source: Zacks Investment Research
EYPT’s DME Pipeline Provides Another Potential Growth Driver
Beyond wet AMD, EyePoint is developing Duravyu for DME. EyePoint has completed enrollment in its two phase III studies, COMO and CAPRI. Both studies are evaluating the candidate against REGN’s Eylea, with treatment designed to be repeated every six months. Top-line results are expected in the fourth quarter of 2027. If the drug shows meaningful benefits in these studies, DME could provide a second major indication and expand Duravyu’s commercial opportunity.
EyePoint, Inc. Price and Consensus
EyePoint, Inc. price-consensus-chart | EyePoint, Inc. Quote
EYPT's Zacks Rank & Estimates
EyePoint currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Over the past 60 days, estimates for EYPT’s 2026 loss per share have narrowed from $3.59 to $3.51, while 2027 loss per share estimates have improved from $2.63 to $2.36.
Other Stocks to Consider
Some other top-ranked stocks in the biotech sector are Amarin AMRN and Corcept Therapeutics CORT, currently sporting a Zacks Rank #1 each.
Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents. AMRN’s shares have lost 17% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%.
Over the past 60 days, earnings per share estimates for Corcept Therapeutics have increased from $1.13 to $1.86 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $2.35 to $3.48. CORT’s shares have skyrocketed 238.5% year to date.
Corcept Therapeutics’ earnings missed estimates in two of the trailing four quarters, beat in one and met in the remaining occasion, with the average surprise being 240.74%.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This innovative software-as-a-service firm upped its user base +22% year over year. That rate is increasing and margins are expanding as AI efficiencies take effect. Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
EyePoint, Inc. (EYPT): Free Stock Analysis Report
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
Amarin Corporation PLC (AMRN): Free Stock Analysis Report
Corcept Therapeutics Incorporated (CORT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).